 |
|
Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease
Inès Dufour, Arnaud Devresse, Anais Scohy, Caroline Briquet, Hélène Georgery, Philippe Delaey, Julien De Greef, Eric Goffin, Laura Labriola
Kidney Res Clin Pract. 2023;42(2):275-278. Published online 2023 Mar 31 DOI: https://doi.org/10.23876/j.krcp.22.194
|
|
Citations to this article as recorded by
 Medication safety in chronic kidney disease
Sonal Singh
Current Opinion in Nephrology & Hypertension.2023; 32(5): 434. CrossRef Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, Michail Papadakis, Ioulia Markaki, Nikolaos Spernovasilis
Infectious Disease Reports.2023; 15(6): 662. CrossRef
|